UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1452-2
Program Prior Authorization/Notification
Medication Agamree® (vamorolone)*
P&T Approval Date 10/2024
Effective Date 1/1/2025
1. Background:
Agamree (vamorolone)* is a corticosteroid indicated for the treatment of Duchenne muscular
dystrophy (DMD) in patients 2 years of age and older.
2. Coverage Criteriaa:
A. Initial Authorization
1. Agamree* will be approved based on the following criterion:
a. Diagnosis of Duchenne muscular dystrophy
Authorization will be issued for 12 months
B. Reauthorization
1. Agamree* will be approved based on the following criterion:
a. Documentation of positive clinical response to Agamree therapy
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
*Agamree is typically excluded from coverage. Tried/Failed criteria may be in place. Please
refer to plan specifics to determine exclusion status.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits, Medical Necessity and/or Step Therapy may be in place.
4. References:
1. Agamree [package insert]. Coral Gables, FL: Catalyst Pharmaceuticals, Inc.; June 2024.
© 2024 UnitedHealthcare Services, Inc.
1
Program Prior Authorization/Notification - Agamree (vamorolone)
Change Control
7/2024 New program.
10/2024 Added exclusion footnote and updated reference.
© 2024 UnitedHealthcare Services, Inc.
2